Regulators say there was a major surge in GLP-1 products, with detentions rising from 1,582 in 2024 to 48,752 in 2025
Lyle Ungar, professor in computer and information science and co-author of the study
In the LEADER study with liraglutide, in patients with CKD stage 3, this cardiovascular benefit proved to be greater.58 Although the cardiovascular safety studies were not powered to detect differences in individual components of MACE, some differences between studies were seen in these individual components
By managing this complex documentation, Novanex enhances the ability of 503A pharmacies to focus on what they do best: meeting individual patient needs
These symptoms are most common during the early stages of treatment or when doses are increased, but they often subside as the body adjusts
Roberts, T